Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
99.48 EUR | -0.92% | +1.95% | +0.72% |
Apr. 24 | CARL ZEISS MEDITEC AG : Gets a Buy rating from UBS | ZD |
Apr. 23 | CARL ZEISS MEDITEC AG : Receives a Sell rating from JP Morgan | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 34.36 and 27.11 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.55 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.72% | 9.6B | B+ | ||
+8.78% | 220B | B | ||
+8.24% | 185B | B- | ||
+11.16% | 133B | B- | ||
+26.12% | 107B | A- | ||
+0.61% | 62.91B | A- | ||
+16.21% | 53.34B | B+ | ||
-1.63% | 47.71B | B+ | ||
-1.11% | 40.29B | A | ||
+12.16% | 39.57B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AFX Stock
- Ratings Carl Zeiss Meditec AG